Literature DB >> 25421796

Hypertension control and antihypertensive therapy in patients with chronic kidney disease.

Sudhir Unni1, Kellee White2, Michael Goodman3, Xiangyang Ye3, Panagiotis Mavros4, Lori D Bash4, Diana Brixner3.   

Abstract

BACKGROUND: Hypertension is a major risk factor in the progression of chronic kidney disease (CKD). Although hypertension is more prevalent and treated more often among CKD patients, it is less likely to be controlled. Current guidelines recommend the use of multiple antihypertensive agents to achieve optimal blood pressure (BP) control. However, BP control attained by number and type of antihypertensive therapy according to CKD stage has not been examined thoroughly. STUDY
DESIGN: Cross-sectional analysis of an electronic medical record (EMR) database. SETTING AND PARTICIPANTS: A total of 115,608 patients with CKD (Stages 1-4) and diagnosed or treated hypertension in General Electric Centricity EMR from 1996 to 2012. OUTCOME: BP control, based on JNC 7 guidelines, was defined as less than 130/80 mm Hg. MEASUREMENTS: BP and antihypertensive therapy use was obtained from the EMR. The Cockcroft-Gault equation was used to calculate estimated glomerular filtration rate and classify CKD stage.
RESULTS: Overall prevalence of BP control was 24.3%. BP control varied by CKD stage and number of antihypertensive therapy. In multivariable analysis, younger age was less likely to be associated with BP control, regardless of CKD stage. Multiple antihypertensive therapy use and BP control was strongest among CKD Stage 2 (odds ratio (OR): 1.41; 95% confidence interval (CI): 1.05, 1.90). Diuretic use was less likely to be associated with BP control among CKD Stage 1 (OR: 0.71; 95% CI: 0.59, 0.87) and 2 (OR: 0.78; 95% CI: 0.72, 0.85). LIMITATIONS: Information on antihypertensive prescription fill data and adherence to medication regimens was unavailable.
CONCLUSIONS: This study highlighted the need to pay closer attention to achieving BP treatment goals for younger individuals with CKD. More research is needed to assess the extent to which specific combinations of antihypertensive drugs leads to adequate BP control. © American Journal of Hypertension, Ltd 2014. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antihypertensive therapy; blood pressure control; chronic kidney disease; electronic medical record; hypertension.

Mesh:

Substances:

Year:  2014        PMID: 25421796     DOI: 10.1093/ajh/hpu215

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

Review 1.  Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz
Journal:  Toxins (Basel)       Date:  2018-06-12       Impact factor: 4.546

2.  A feared combination: Hypertension and chronic kidney disease.

Authors:  Paola Varleta; Rodrigo Tagle
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-11-14       Impact factor: 3.738

3.  Physical Activity In Renal Disease (PAIRED) and the effect on hypertension: study protocol for a randomized controlled trial.

Authors:  Stephanie Thompson; Natasha Wiebe; Gabor Gyenes; Rachelle Davies; Jeyasundar Radhakrishnan; Michelle Graham
Journal:  Trials       Date:  2019-02-08       Impact factor: 2.279

4.  Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney Disease.

Authors:  Donald J Weaver; Anne Waldo; Gia J Oh; Elaine S Kamil; Matthew Elliott; Sharon Adler; Anne Pesenson; Meg M Modes; Patrick Gipson; Richard A Lafayette; David T Selewski; Samara E Attalla; Richard Eikstadt; Jonathan P Troost; Debbie S Gipson; Susan F Massengill
Journal:  Kidney Med       Date:  2020-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.